Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.
Publication
, Journal Article
Fong, Y; Dang, L; Zhang, B; Fintzi, J; Chen, S; Wang, J; Rouphael, NG; Branche, AR; Diemert, DJ; Falsey, AR; Losada, C; Baden, LR; Frey, SE ...
Published in: Clin Infect Dis
February 5, 2025
For COVAIL recipients of a coronavirus disease 2019 (COVID-19) Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were inverse CoRs with covariate-adjusted hazard ratios (95% confidence intervals) 0.30 (0.11, 0.78) and 0.25 (0.07, 0.85) per 10-fold increase in weighted average titer.
Duke Scholars
Published In
Clin Infect Dis
DOI
EISSN
1537-6591
Publication Date
February 5, 2025
Volume
80
Issue
1
Start / End Page
223 / 227
Location
United States
Related Subject Headings
- Vaccines, Synthetic
- SARS-CoV-2
- Middle Aged
- Microbiology
- Male
- Immunization, Secondary
- Humans
- Female
- COVID-19 Vaccines
- COVID-19
Citation
APA
Chicago
ICMJE
MLA
NLM
Fong, Y., Dang, L., Zhang, B., Fintzi, J., Chen, S., Wang, J., … Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team. (2025). Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial. Clin Infect Dis, 80(1), 223–227. https://doi.org/10.1093/cid/ciae465
Fong, Youyi, Lauren Dang, Bo Zhang, Jonathan Fintzi, Shiyu Chen, Jing Wang, Nadine G. Rouphael, et al. “Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.” Clin Infect Dis 80, no. 1 (February 5, 2025): 223–27. https://doi.org/10.1093/cid/ciae465.
Fong Y, Dang L, Zhang B, Fintzi J, Chen S, Wang J, et al. Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial. Clin Infect Dis. 2025 Feb 5;80(1):223–7.
Fong, Youyi, et al. “Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.” Clin Infect Dis, vol. 80, no. 1, Feb. 2025, pp. 223–27. Pubmed, doi:10.1093/cid/ciae465.
Fong Y, Dang L, Zhang B, Fintzi J, Chen S, Wang J, Rouphael NG, Branche AR, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Kamidani S, Walter EB, Novak RM, Rupp R, Jackson LA, Yu C, Magaret CA, Molitor C, Borate B, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Bäcker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Atmar RL, Posavad CM, Mu J, Makowski M, Makhene MK, Nayak SU, Roberts PC, Follmann D, Gilbert PB, Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team. Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial. Clin Infect Dis. 2025 Feb 5;80(1):223–227.
Published In
Clin Infect Dis
DOI
EISSN
1537-6591
Publication Date
February 5, 2025
Volume
80
Issue
1
Start / End Page
223 / 227
Location
United States
Related Subject Headings
- Vaccines, Synthetic
- SARS-CoV-2
- Middle Aged
- Microbiology
- Male
- Immunization, Secondary
- Humans
- Female
- COVID-19 Vaccines
- COVID-19